KRYSTAL-12: Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

KRYSTAL 849-012: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

  • Clinical Trial Information

    Trial Contact: Thomas, Andrea L

    Trial Phone: 321.841.8284

  • IRB No: S21.015.01

    Protocol Abbrev: KRYSTAL 849-012

    Principal Investigator: Tirrell Tremayne Johnson, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: KRYSTAL 849-012

    Treatment: Investigational agent MRTX849 or Docetaxel

    Therapies Involved: Chemotherapy ID: NCT04685135

  • Objective

    To compare the efficacy of MRTX849 versus docetaxel in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.

  • Key Eligibility

    -Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.

    -Candidacy to receive treatment with docetaxel.

    -18 years and older